EIT Pharma Announces FDA Acceptance of New Drug Application for Lonafarnib for Treatment of Chronic Hepatitis D
EIT Pharma Announces FDA Acceptance of New Drug Application for Lonafarnib for Treatment of Chronic Hepatitis D
EIT Pharma
Private
Biopharmaceutical company developing lonafarnib for chronic hepatitis delta (HDV), a serious liver infection. NDA accepted by FDA in 2026.
Company Info
Upcoming Milestones & Key Dates
2026/2027
Regulatory
PDUFA date for lonafarnib NDA